-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The induction therapy of oral proteasome inhibitor ixazomib has shown good efficacy and safety in clinical trials, but its experience in real life is still limited
COVID-19 diagnosis
The treatment regimen based on ixazomib included 44.
Ten patients received maintenance treatment with ixazomib
In summary, these results support ixazomib as a first-line therapy in routine practice, and the toxicity of ixazomib can be tolerated.
Original source:
Jing Li ,Li Bao , et al.
Li jing Li Bao Ixazomib-based Frontline Therapy in patients with newly diagnosed Multiple myeloma in Real-Life Practice Showed the Comparable efficacy and Safety Profile with Those Reported in Clinical Trial: A Multi-Center Study
in this message